Valpress Comp Filmuhúðuð tafla 160/12,5 mg Islanda - islandese - LYFJASTOFNUN (Icelandic Medicines Agency)

valpress comp filmuhúðuð tafla 160/12,5 mg

teva b.v.* - valsartanum inn; hydrochlorothiazidum inn - filmuhúðuð tafla - 160/12,5 mg

Valpress Comp Filmuhúðuð tafla 80/12,5 mg Islanda - islandese - LYFJASTOFNUN (Icelandic Medicines Agency)

valpress comp filmuhúðuð tafla 80/12,5 mg

teva b.v.* - valsartanum inn; hydrochlorothiazidum inn - filmuhúðuð tafla - 80/12,5 mg

Valsartan/Hydrochlorothiazide Krka Filmuhúðuð tafla 160 mg/12,5 mg Islanda - islandese - LYFJASTOFNUN (Icelandic Medicines Agency)

valsartan/hydrochlorothiazide krka filmuhúðuð tafla 160 mg/12,5 mg

krka sverige ab - hydrochlorothiazide; valsartanum inn - filmuhúðuð tafla - 160 mg/12,5 mg

Valsartan/Hydrochlorothiazide Krka Filmuhúðuð tafla 160 mg/25 mg Islanda - islandese - LYFJASTOFNUN (Icelandic Medicines Agency)

valsartan/hydrochlorothiazide krka filmuhúðuð tafla 160 mg/25 mg

krka sverige ab - hydrochlorothiazide; valsartanum inn - filmuhúðuð tafla - 160 mg/25 mg

Valsartan/Hydrochlorothiazide Krka Filmuhúðuð tafla 80 mg/12,5 mg Islanda - islandese - LYFJASTOFNUN (Icelandic Medicines Agency)

valsartan/hydrochlorothiazide krka filmuhúðuð tafla 80 mg/12,5 mg

krka sverige ab - valsartanum inn; hydrochlorothiazide - filmuhúðuð tafla - 80 mg/12,5 mg

Pylclari Unione Europea - islandese - EMA (European Medicines Agency)

pylclari

curium pet france - piflufolastat (18f) - blöðruhálskirtli - greining geislavirkja - Þetta lyf er eingöngu ætlað til greiningar. pylclari is indicated for the detection of prostate-specific membrane antigen (psma) positive lesions with positron emission tomography (pet) in adults with prostate cancer (pca) in the following clinical settings:primary staging of patients with high-risk pca prior to initial curative therapy,to localize recurrence of pca in patients with a suspected recurrence based on increasing serum prostate-specific antigen (psa) levels after primary treatment with curative intent. pylclari is indicated for use with positron emission tomography (pet).

Evrysdi Unione Europea - islandese - EMA (European Medicines Agency)

evrysdi

roche registration gmbh  - risdiplam - vöðvaáfall, mænu - Önnur lyf við sjúkdómum í stoðkerfi - evrysdi is indicated for the treatment of 5q spinal muscular atrophy (sma) in patients with a clinical diagnosis of sma type 1, type 2 or type 3 or with one to four smn2 copies.